Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI
Retrieved on:
Thursday, December 1, 2022
COVID-19, Doctor of Philosophy, University of Copenhagen, Peripheral nervous system, DNA repair, AI, University, Chemistry, DNA, Gene, Degenerative disease, Associate, Patient, Survival analysis, Ageing, Biomarker, Insilico Medicine, Disease, MD, PLK1, Human, Assistant, Cancer, Cell division, ALS, Hope, Chicago (franchise), Research, Immunity, Gene expression, Intelligence, Fibrosis, Publication, Nature Cell Biology, Medicine, Sarcoma, Survival, Amyotrophic lateral sclerosis, University of Copenhagen Faculty of Health and Medical Sciences, Biology, Longevity, Safety, Idiopathic pulmonary fibrosis, Algorithm, Medical device, Pharmaceutical industry, Vaccine, CEP135
The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .
Key Points:
- The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .
- With the most significantly perturbed genes serving as biomarkers, researchers performed survival analysis across 33 cancer types and selected those that showed high confidence stratification among cancer patients.
- Insilico Medicines AI-driven PandaOmics platform was used to perform a comprehensive differential gene expression analysis, survival stratification, and target discovery.
- Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.